Construction has begun at the RNA Research and Pilot Manufacturing Facility at Macquarie University’s main campus, northwest of Sydney’s CBD, with completion scheduled for 2026. In a statement on Monday, the NSW government said the upcoming facility will allow for a “wide range of RNA vaccines, therapeutics and delivery technologies to be independently designed and…
IDT Australia secures Sanofi contract Pharmaceutical development company IDT Australia has secured a follow on contract with pharma giant Sanofi Australia for preclinical formulation, development and manufacture of Sanofi’s messenger RNA (mRNA). The contract, worth up to $4 million, continues the company’s advancement of mRNA-based vaccine formulation, development and manufacture at IDT’s aseptic sterile injectables…
A new mRNA cancer vaccine hub at the Australian Institute for Bioengineering and Nanotechnology in Brisbane is expected to be operating by late-this year, The University of Queensland has shared. In a statement on Monday, UQ said the BASE mRNA facility was supported by a recent $3.3 million Medical Research Future Fund National Critical Research…
The federal government has released Australia’s RNA Blueprint, which it says will “guide advanced manufacturing growth and help create more high-paying jobs” within a sector estimated to add “up to $8 billion” to national GDP over the next decade. In a statement on Tuesday, industry minister Ed Husic said the blueprint (available here) focussed on…
Psychotropic medicines manufacturer Mynd Bio Pty Ltd has made a surprise bid to acquire listed pharmaceutical developer, Melbourne-based IDT Australia. The bidder is part of a larger group which has already invested in a group of pharmaceutical companies that develop psychotropic medicines, planning to set up manufacturing in Portugal to tackle the European market. The…
IDT Australia to raise $7 million for mRNA vaccine production Pharmaceutical manufacturer IDT Australia is to raise $7 million a fully underwritten entitlement offer of fully paid ordinary shares to eligible shareholders. The funds raised will be used to fund capital expenditure relating to current and potential future works in the mRNA therapeutics field including…
Are we actually asking the question in our editorial series – Towards 3% R&D – Turbocharging Australia’s Innovation Effort. Here Allen Roberts looks behind the issue at the Australian way of getting things done, and whether that, itself, needs reform. As we seek to move towards 3% of GDP as a measure of the R&D…
Drug development company IDT Australia and pharmaceutical business Sanofi have signed an agreement for the good manufacturing practice (cGMP) manufacture of Sanofi’s mRNA vaccines now under development. The partners will collaborate to advance mRNA-based vaccine formulation, development and manufacture at IDT’s aseptic sterile injectables filling facilities in Melbourne (pictured) in volumes needed for clinical trials…
Envirostream to recycle LG lithium batteries Battery recycler Envirostream has signed an exclusive three year agreement with LG Energy Solutions to recycle all its recalled lithium ion batteries collected in Australia. Envirostream, a subsidiary of Lithium Australia, expects significantly increased battery collection volumes equating to 140 percent of the company’s total in FY23. LG has…
Microbial development and contract manufacturing companies Adelaide’s BioCina and Perth’s NovaCina have announced a strategic partnership to provide integrated drug substance and drug product solutions for the pharmaceutical sector. The two companies are buy-outs from the Pfizer pharmaceutical company and share the same investor – private investment firm Bridgewest Group – and will now collaborate…
